Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Bioavailability Enhancement: Drug Permeability Enhancement

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...

Ischemic Stroke ll: Pathophysiology

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

Modified-Release Drug Delivery Systems: Influencing Factors

Modified-Release Drug Delivery Systems: Influencing Factors

Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer.

Frontiers in immunology·2026

Same author

Green Synthesis of Alkyl Carbamates via Non-Phosgene Process From Reactions of NH<sub>3</sub> and Dialkyl Carbonate Over Zn-Acetate-Triazolato Catalysts.

ChemSusChem·2026

Same author

Nomogram with late neurological deterioration as a key predictor for poor functional outcomes after endovascular therapy in acute basilar artery occlusion beyond 24 hours.

Stroke and vascular neurology·2026

Same author

DNA hypermethylation of FGFR2 drives fibrosis in the aging kidney.

Scientific reports·2026

Same author

Experimental Study on Wettability Reversal in Coal Reservoirs Induced by the Synergy of Nitrogen and Surfactant.

ACS omega·2026

Same author

A comprehensive map of key aroma-active compounds in cigar tobacco via GC-IMS and GC-O-MS.

Frontiers in plant science·2026

Search research articles

Related Experiment Video

Updated: May 29, 2026

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Targeting ischemic penumbra Part II: selective drug delivery using liposome technologies.

Shimin Liu¹, Steven R Levine, H Richard Winn

¹Department of Neurology, Boston University School of Medicine, Boston, USA.

Journal of Experimental Stroke & Translational Medicine

|September 13, 2011

Summary

Liposome technology offers promising solutions for delivering drugs to ischemic brain tissue, overcoming barriers for effective neuroprotection in acute ischemic stroke treatment.

More Related Videos

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Related Experiment Videos

Last Updated: May 29, 2026

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Area of Science:

Neuroscience
Biotechnology
Pharmacology

Background:

Acute ischemic stroke poses significant challenges for drug delivery to the brain.
Existing treatments face barriers in reaching ischemic brain tissue effectively.
Brain ischemia induces metabolic and structural changes complicating drug transport.

Purpose of the Study:

To review the challenges and potential of liposome-based drug delivery for ischemic brain tissue.
To build upon the concept of selective drug delivery to ischemic brain tissue for neuroprotection.
To explore how liposomes can overcome barriers in treating acute ischemic stroke.

Main Methods:

Review of existing literature on liposome technology and brain drug delivery.
Analysis of ischemia-induced changes in the brain microenvironment.
Discussion of liposome targeting strategies for ischemic tissues.

Main Results:

Liposomes can navigate biological barriers to reach the brain.
Liposomes can be engineered to exploit ischemia-induced changes for selective targeting.
This approach offers a promising strategy for neuroprotection in stroke.

Conclusions:

Liposome drug delivery systems show significant promise for targeting ischemic brain tissue.
Utilizing ischemia-specific changes enhances the selectivity of liposome delivery.
This technology represents a potential advancement in neuroprotective treatments for acute ischemic stroke.